RheOxTM Technology
Chronic Bronchitis
)
Clinical Evidence
)
Bronchial Rheoplasty
Procedure
Currently Enrolling
Clinical Studies
)
RheOxTM
RheOx is system comprised of a single use catheter and electrosurgical generator. A physician uses the system to deliver non-thermal energy to the airways to reduce mucus-producing cells in patients with Chronic Bronchitis.
Non-Thermal, Targeted Energy Delivery
- Pulsed electric fields target abnormal cells, leaving extracellular matrix intact
- Rapid regeneration of epithelium1
- RheOx Catheter is delivered through a bronchoscope by a single operator
Newswire
Latest News, Events & Information from Gala Therapeutics
Gala Therapeutics Receives FDA Approval to Commence Pivotal Trial to Evaluate the RheOxTM System for Chronic Bronchitis
San Carlos, CA – Feb. 22, 2021 – Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, announces U.S. Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE) approval to commence its pivotal clinical trial called RheSolve,
…
Gala Therapeutics’ RheOxTM System Showcased in Live Case at Virtual European Respiratory Society (ERS) Congress as Part of Post-Market Chronic Bronchitis Study
Menlo Park, CA, Sept. 9, 2020 – Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, today announced that a live case featuring its RheOxTM Bronchial Rheoplasty System was performed during the virtual European Respiratory Society (ERS) International Congress 2020.
…
Gala Therapeutics Announces Publication of Multicenter Study of the Minimally Invasive RheOxTM System in Patients with Chronic Bronchitis
New Clinical Results from RheOxTM System for Chronic Bronchitis to be Presented at European Respiratory Society (ERS) International Congress
Menlo Park, Calif. – Sept. 26, 2019 – Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, today announced that clinical results and a patient case involving its RheOxTM Bronchial Rheoplasty system will be presented at the 2019 ERS International Congress,
…
Gala Therapeutics Receives FDA Breakthrough Device Designation for the Minimally Invasive RheOxTM System for Chronic Bronchitis
Menlo Park, CA Sept. 16, 2019 – Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation (FDA) for the RheOxTM Bronchial RheoplastyTM system.
…
Gala Therapeutics Receives CE Mark for its Minimally Invasive RheOxTM System for Chronic Bronchitis
First-of-its-kind RheOx device designed to reduce mucus-producing cells and improve quality of life
Menlo Park, CA Sept. 4, 2019 – Gala Therapeutics, Inc. (Gala) today announced that its RheOxTM system has received CE Mark in the European Union.
…
Initial Study of the Minimally Invasive RheOxTM Device Demonstrates Positive Results for Chronic Bronchitis Patients
Dallas, Texas, May 22, 2019 – Gala Therapeutics, Inc. (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced new results from the initial study of its investigational RheOxTM device,
…
New Data from First-in-Human Study of RheOxTM Device-Based Therapy for Chronic Bronchitis to be Presented at ATS 2019
Menlo Park, Calif., May 16, 2019 – Gala Therapeutics, Inc. (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that data from the first-in-human study of its investigational RheOxTM device will be presented at the 2019 American Thoracic Society (ATS) International Conference,
…
Gala Enrolls First Subject at Temple Lung Center as Part of the US Early Feasibility Trial of RheOxTM for Chronic Bronchitis in the United States
Menlo Park, Calif, November 5, 2018 – Gala Therapeutics (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that the first patient at Temple Lung Center in Philadelphia,
…
Pittsburgh’s KDKA Publishes Story on the First Patient Treated with RheOxTM in the United States
…
Contact Us
- Fernandez-Bussy et al. Histopathologic Results Post Bronchial Rheoplasty. ATS 2019, Dallas, TX.
- FastStats - Chronic Lower Respiratory Disease. Centers for Disease Control (CDC) / National Center for Health Statistics (NCHS) 2017; https://www.cdc.gov/nchs/fastats/copd.htm
- Criner, G. Chronic Bronchitis: The Case for an Unmet Medical Need. ERS 2017, Milan, Italy
- Health at a Glance: Europe (2012 and 2014 reports) http://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-europe-2012_9789264183896-en
- Cerveri, et al, Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults; Eur Respir J 2001; 18: 85–92
- Kim et al. The Chronic Bronchitic Phenotype of COPD: An analysis of the COPD Gene Study CHEST 2011; 140(3):626–633
- Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available from: https://goldcopd.org.
- A. Valipour, et al. Bronchial Rheoplasty For Treatment of Chronic Bronchitis: 12 Month Results from a Multi-Center Study. Am J Respir Crit Care Med 2020;
Article in Press.
Our Social Sphere
Gala Therapeutics Receives FDA Approval to Commence Pivotal Trial to Evaluate the RheOxTM System for Chronic Bronchitis
Gala Therapeutics’ RheOx™ System Showcased in Live Case at Virtual European Respiratory Society (ERS) Congress as Part of Post-Market Chronic…
COPD: Positive Data for RheOx Bronchial Rheoplasty System
New Clinical Results from RheOxTM System for Chronic Bronchitis to be Presented at European Respiratory Society (ERS) International Congress
Gala Therapeutics Receives FDA Breakthrough Device Designation for the Minimally Invasive RheOxTM System for Chronic Bronchitis
Gala Therapeutics Receives CE Mark for its Minimally Invasive RheOxTM System for Chronic Bronchitis
Initial Study of the Minimally invasive RheOxTM Device…
Come hear about Bronchial Rheoplasty with RheOx at the European Respiratory Conference in Madrid
FOLLOW US